PMID- 12574326
OWN - NLM
STAT- MEDLINE
DCOM- 20030425
LR  - 20201219
IS  - 0022-1767 (Print)
IS  - 0022-1767 (Linking)
VI  - 170
IP  - 4
DP  - 2003 Feb 15
TI  - Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile 
      vaccination against tumors by dendritic cells.
PG  - 1641-8
AB  - Dendritic cells (DCs) loaded with tumor-associated Ags (TAAs) act as potent 
      adjuvant that initiates antitumor immune responses in vivo. However, TAA-based DC 
      vaccination requires prior identification of TAAs. Apoptotic tumor cells (ATCs) 
      can be an excellent source for DC loading because their potential uncharacterized 
      Ags would be efficiently presented to T cells without any prior characterization 
      and isolation of these Ags. However, ATCs alone are considered to be inefficient 
      for activating antitumor immunity, possibly because of their inability to induce 
      DC maturation. In this study, the aim was to enhance antitumor immune response by 
      taking advantage of ATCs that have been opsonized with IgG (ATC-immune complexes, 
      ATC-ICs) so as to target them to FcR for IgG (FcgammaRs) on DCs. It was found 
      that when compared with ATCs, ATC-ICs were efficiently internalized by DCs via 
      FcgammaRs, and this process induced maturation of DCs, which was more efficient 
      than that of ATCs. Importantly, ATC-IC loading was shown to be more efficient 
      than ATCs alone in its capacity for inducing antitumor immunity in vivo, in terms 
      of cytotoxic T cell induction and tumor rejection. These results show that using 
      ATC-ICs may overcome the limitations and may enhance the immune response of 
      current ATC-based DC vaccination therapy.
FAU - Akiyama, Kenichi
AU  - Akiyama K
AD  - Department of Experimental Immunology and Core Research for Evolutional Science 
      and Technology, Japan Science and Technology Corporation, Sendai, Japan.
FAU - Ebihara, Shin
AU  - Ebihara S
FAU - Yada, Ayumi
AU  - Yada A
FAU - Matsumura, Kimio
AU  - Matsumura K
FAU - Aiba, Setsuya
AU  - Aiba S
FAU - Nukiwa, Toshihiro
AU  - Nukiwa T
FAU - Takai, Toshiyuki
AU  - Takai T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Immunol
JT  - Journal of immunology (Baltimore, Md. : 1950)
JID - 2985117R
RN  - 0 (Antigen-Antibody Complex)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Receptors, IgG)
RN  - 9006-59-1 (Ovalbumin)
SB  - IM
MH  - Animals
MH  - Antigen Presentation
MH  - Antigen-Antibody Complex/metabolism
MH  - Apoptosis/genetics/*immunology
MH  - B-Lymphocyte Subsets/immunology
MH  - Cancer Vaccines/administration & dosage/*immunology
MH  - Cell Differentiation/immunology
MH  - Cytotoxicity, Immunologic/immunology
MH  - Dendritic Cells/cytology/*immunology/*metabolism/transplantation
MH  - Female
MH  - Germinal Center/cytology/immunology
MH  - Histocompatibility Antigens Class II/immunology
MH  - Immunotherapy, Adoptive/methods
MH  - Injections, Subcutaneous
MH  - Lymphocyte Activation/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Ovalbumin/immunology/metabolism
MH  - Receptors, IgG/deficiency/genetics/*metabolism
MH  - T-Lymphocytes, Cytotoxic/immunology
MH  - Thymoma/genetics/*immunology/*pathology/prevention & control
MH  - Tumor Cells, Cultured
EDAT- 2003/02/08 04:00
MHDA- 2003/04/26 05:00
CRDT- 2003/02/08 04:00
PHST- 2003/02/08 04:00 [pubmed]
PHST- 2003/04/26 05:00 [medline]
PHST- 2003/02/08 04:00 [entrez]
AID - 10.4049/jimmunol.170.4.1641 [doi]
PST - ppublish
SO  - J Immunol. 2003 Feb 15;170(4):1641-8. doi: 10.4049/jimmunol.170.4.1641.